RecruitingNCT05392881
Interstitial Lung Disease Research Unit Biobank
University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank
Sponsor
University of Kansas Medical Center
Enrollment
1,000 participants
Start Date
Aug 9, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This biobank study at the University of Kansas Medical Center is collecting blood and tissue samples from patients with interstitial lung disease (ILD), autoimmune diseases, or other rare lung conditions. By storing these samples in a research biobank, scientists can study the biological causes of these diseases and develop better tests and treatments in the future.
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05392881
Related Trials
Ultrasound and Respiratory Physiological Signals in Lung Diseases
NCT060686471 location
A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants
NCT074542912 locations
Skeletal Muscle Function in Interstitial Lung Disease
NCT038000171 location
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
NCT0703652347 locations
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622373 locations